The p73 Tumor Suppressor Is Targeted by Pirh2 RING Finger E3 Ubiquitin Ligase for the Proteasome-dependent Degradation

被引:34
作者
Jung, Yong-Sam [1 ]
Qian, Yingjuan [1 ]
Chen, Xinbin [1 ]
机构
[1] Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA
基金
美国国家卫生研究院;
关键词
DNA-POLYMERASE-ETA; P53; FAMILY; PROTEIN LIGASE; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVITY; SV40-TRANSFORMED CELLS; APOPTOTIC RESPONSE; GENE-EXPRESSION; REGULATES P73; HUMAN CANCER;
D O I
10.1074/jbc.M111.261537
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p73 gene, a homologue of the p53 tumor suppressor, is expressed as TA and Delta N isoforms. TAp73 has similar activity as p53 and functions as a tumor suppressor whereas Delta Np73 has both pro-and anti-survival functions. While p73 is rarely mutated in spontaneous tumors, the expression status of p73 is linked to the sensitivity of tumor cells to chemotherapy and prognosis for many types of human cancer. Thus, uncovering its regulators in tumors is of great interest. Here, we found that Pirh2, a RING finger E3 ubiquitin ligase, promotes the proteasome-dependent degradation of p73. Specifically, we showed that knockdown of Pirh2 up-regulates, whereas ectopic expression of Pirh2 down-regulates, expression of endogenous and exogenous p73. In addition, Pirh2 physically associates with and promotes TAp73 polyubiquitination both in vivo and in vitro. Moreover, we found that p73 can be degraded by both 20 S and 26 S proteasomes. Finally, we showed that Pirh2 knockdown leads to growth suppression in a TAp73-dependent manner. Taken together, our findings indicate that Pirh2 promotes the proteasomal turnover of TAp73, and thus targeting Pirh2 to restore TAp73-mediated growth suppression in p53-deficient tumors may be developed as a novel anti-cancer strategy.
引用
收藏
页码:35388 / 35395
页数:8
相关论文
共 57 条
[1]   A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73 [J].
Asher, G ;
Tsvetkov, P ;
Kahana, C ;
Shaul, Y .
GENES & DEVELOPMENT, 2005, 19 (03) :316-321
[2]   Mdm2 binds p73α without targeting degradation [J].
Bálint, E ;
Bates, S ;
Vousden, KH .
ONCOGENE, 1999, 18 (27) :3923-3929
[3]   p53 ubiquitination: Mdm2 and beyond [J].
Brooks, CL ;
Gu, W .
MOLECULAR CELL, 2006, 21 (03) :307-315
[4]   p73 is transcriptionally regulated by DNA damage, p53, and p73 [J].
Chen, XB ;
Zheng, YM ;
Zhu, JH ;
Jiang, JY ;
Wang, J .
ONCOGENE, 2001, 20 (06) :769-774
[5]  
Corn PG, 1999, CANCER RES, V59, P3352
[6]   p63 and p73 in human cancer: defining the network [J].
DeYoung, M. P. ;
Ellisen, L. W. .
ONCOGENE, 2007, 26 (36) :5169-5183
[7]   Phosphorylation of Pirh2 by Calmodulin-dependent kinase II impairs its ability to ubiquitinate p53 [J].
Duan, Shanshan ;
Yao, Zhan ;
Hou, Dezhi ;
Wu, Zhengsheng ;
Zhu, Wei-Guo ;
Wu, Mian .
EMBO JOURNAL, 2007, 26 (13) :3062-3074
[8]   Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells [J].
Duan, Wenrui ;
Gao, Li ;
Wu, Xin ;
Zhang, Yang ;
Otterson, Gregory A. ;
Villalona-Calero, Miguel A. .
EXPERIMENTAL CELL RESEARCH, 2006, 312 (17) :3370-3378
[9]   Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer [J].
Duan, WR ;
Gao, L ;
Druhan, LJ ;
Zhu, WG ;
Morrison, C ;
Otterson, GA ;
Villalona-Calero, MA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (22) :1718-1721
[10]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49